MIM
RVMD icon

MetLife Investment Management’s Revolution Medicines RVMD Stock Holding History

MetLife Investment Management’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.99M Buy
10,635
+7,847
+281% +$1.15M 0.01% 1153
2026
Q1 		$271K Sell
2,788
-750
-21% -$75.7K ﹤0.01% 2069
2025
Q4 		$282K Buy
3,538
+648
+22% +$42.5K ﹤0.01% 2101
2025
Q3 		$135K Buy
2,890
+3
+0.1% +$117 ﹤0.01% 2518
2025
Q2 		$106K Sell
2,887
-95,999
-97% -$3.69M ﹤0.01% 2513
2025
Q1 		$3.5M Sell
98,886
-1,443
-1% -$58.6K 0.02% 792
2024
Q4 		$4.39M Buy
100,329
+13,918
+16% +$702K 0.02% 636
2024
Q3 		$3.92M Sell
86,411
-1,501
-2% -$65.4K 0.02% 669
2024
Q2 		$3.41M Buy
87,912
+16,705
+23% +$624K 0.02% 709
2024
Q1 		$2.3M Sell
71,207
-4,190
-6% -$124K 0.02% 898
2023
Q4 		$2.16M Buy
75,397
+21,936
+41% +$527K 0.02% 919
2023
Q3 		$1.48M Hold
53,461
– – 0.01% 1035
2023
Q2 		$1.43M Buy
53,461
+7,885
+17% +$193K 0.01% 1075
2023
Q1 		$987K Buy
45,576
+6,059
+15% +$149K 0.01% 1228
2022
Q4 		$941K Hold
39,517
– – 0.01% 1251
2022
Q3 		$779K Buy
39,517
+5,261
+15% +$116K 0.01% 1319
2022
Q2 		$668K Hold
34,256
– – 0.01% 1469
2022
Q1 		$874K Buy
34,256
+12,643
+58% +$275K 0.01% 1415
2021
Q4 		$544K Hold
21,613
– – ﹤0.01% 1458
2021
Q3 		$595K Hold
21,613
– – 0.01% 1428
2021
Q2 		$686K Buy
21,613
+4,956
+30% +$173K 0.01% 1388
2021
Q1 		$764K Hold
16,657
– – 0.01% 1279
2020
Q4 		$659K Hold
16,657
– – 0.01% 1335
2020
Q3 		$580K Buy
16,657
+9,645
+138% +$267K 0.01% 1296
2020
Q2 		$221K Hold
7,012
– – ﹤0.01% 1850
2020
Q1 		$154K Buy
+7,012
New +$194K ﹤0.01% 1838

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

MetLife Investment Management's RVMD Position: Q2 2026 in Review

MetLife Investment Management increased its Revolution Medicines (RVMD) stake by 281% in Q2 2026, buying an estimated $1.15M and bringing the position to 10,635 shares worth $1.99M. The position accounts for 0.01% of the portfolio, ranked #1153.

MetLife Investment Management first reported a position in RVMD in Q1 2020 and has held it in 26 quarters since. The position peaked at $4.39M in Q4 2024. 694 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • MetLife Investment Management held 10,635 shares of Revolution Medicines worth $1.99M as of Q2 2026.
  • MetLife Investment Management bought 7,847 Revolution Medicines shares in Q2 2026, an estimated $1.15M.
  • Revolution Medicines made up 0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1153 holding.
  • MetLife Investment Management first reported a position in Revolution Medicines in Q1 2020 and has held it in 26 quarters since.
  • MetLife Investment Management's Revolution Medicines position peaked at $4.39M in Q4 2024.
  • 694 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.